Recalls / Class II
Class IID-0759-2023
Product
Glimepiride Tablets, USP, 4 mg, RX, Packaged as a) 100-count bottle, NDC# 68001-179-00; b) 500-count bottle, NDC# 68001-179-03, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. INDIA. For BluePoint Laboratories
- Affected lot / code info
- Batches a) P2003403, EXP 05/31/2023; P2006593, EXP 11/30/2023; P2101152, EXP 01/31/2024; P2105014, EXP 06/30/2024; R2101440, EXP 09/30/2024; P2200774, EXP 01/31/2025; R2200664, EXP 04/30/2025 b) P2100705, EXP 01/31/2024; P2104672, EXP 06/30/2024; R2101435, EXP 09/30/2024; R2200102, EXP 12/31/2024; R2200577, EXP 04/30/2025; P2205870, EXP 08/31/2025 [500 count] Lot, expiry: P2100121, exp 11/30/2023; P2100705, exp 01/31/2024; P2104672, exp 06/30/2024; R2101435, exp 09/30/2024; R2200102, exp 12/31/2024; R2200577, exp R2200577;P2205870, exp 08/31/2025
Why it was recalled
CGMP Deviations: recalling drug products following an FDA inspection.
Recalling firm
- Firm
- Amerisource Health Services LLC
- Notification channel
- Letter
- Type
- Voluntary: Firm initiated
- Address
- 2550 John Glenn Ave Ste A, N/A, Columbus, Ohio 43217-1188
Distribution
- Quantity
- 129,849 bottles
- Distribution pattern
- Nationwide USA
Timeline
- Recall initiated
- 2023-03-17
- FDA classified
- 2023-05-19
- Posted by FDA
- 2023-05-31
- Terminated
- 2024-09-06
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-0759-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.